APR Sept/Oct 2023 - 66
»
FORMULATION AND DEVELOPMENT
»
9.
10.
Addison E, Keinan S. Using Quantum Molecular Design & Cloud Computing to Improve the
Accuracy & Success Probability of Drug Discovery. Drug Development & Delivery. March
2016, Vol 16 No 2.
Sekharan S, Wei JN, Batista VS. The active site of melanopsin: the biological clock
photoreceptor. J Am Chem Soc. 2012 Dec 5;134(48):19536-9. doi: 10.1021/ja308763b.
Epub 2012 Nov 19. PMID: 23145979.
11. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase
inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000 Jan;105(1):3-7. doi:
10.1172/JCI9083. PMID: 10619854; PMCID: PMC382593.
12.
13.
14.
Haenlein, M., & Kaplan, A. (2019). A Brief History of Artificial Intelligence: On the Past,
Present, and Future of Artificial Intelligence. California Management Review, 61(4), 5-14.
https://doi.org/10.1177/0008125619864925.
MIT Management. Machine Learning Explained. Sara Brown, April 2021. Accessed on
May 11, 2023, at https://mitsloan.mit.edu/ideas-made-to-matter/machine-learningexplained.
Yu
W, MacKerell AD Jr. Computer-Aided Drug Design Methods. Methods Mol Biol.
2017;1520:85-106. doi: 10.1007/978-1-4939-6634-9_5. PMID: 27873247; PMCID:
PMC5248982.
15. Arodola OA, Soliman ME. Quantum mechanics implementation in drug-design workflows:
does it really help? Drug Des Devel Ther. 2017 Aug 31;11:2551-2564. doi: 10.2147/DDDT.
S126344. Erratum in: Drug Des Devel Ther. 2017 Nov 08;11:3205. PMID: 28919707; PMCID:
PMC5587087.
16. Arodola OA, Soliman ME. Quantum mechanics implementation in drug-design workflows:
does it really help? Drug Des Devel Ther. 2017 Aug 31;11:2551-2564. doi: 10.2147/DDDT.
S126344. Erratum in: Drug Des Devel Ther. 2017 Nov 08;11:3205. PMID: 28919707; PMCID:
PMC5587087.
17.
18.
Kar R. Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical
systems. Drug Discovery Today, Volume 28, Issue 1, 2023. https://doi.org/10.1016/j.
drudis.2022.103374.
Dalal, V., Dhankhar, P., Singh, V. et al. Structure-Based Identification of Potential Drugs Against
FmtA of Staphylococcus aureus: Virtual Screening, Molecular Dynamics, MM-GBSA, and QM/
MM. Protein J 40, 148-165 (2021). https://doi.org/10.1007/s10930-020-09953-6.
66 |
| September/October 2023
19.
Kulkarni U. Prajakta , Shah Harshil and Vyas K. Vivek*, Hybrid Quantum Mechanics/
Molecular Mechanics (QM/MM) Simulation: A Tool for Structure-Based Drug Design and
Discovery, Mini-Reviews in Medicinal Chemistry 2022; 22(8) . https://dx.doi.org/10.2174/
1389557521666211007115250
20.
McKinsey Digital. Security as code: The best (and maybe only) path to securing cloud
applications and systems. Accessed here on May 12, 2023.
21. Gartner. Is the cloud secure? October 10, 2019. Accessed here on May 12, 2023.
22.
Rai, Brajesh K; Sresht, Vishnu; Yang, Qingyi; Unwalla, Ray; Tu, Meihua; Mathiowetz, Alan
M.; and Bakken, Gregory A. Comprehensive Assessment of Torsional Strain in Crystal
Structures of Small Molecules and Protein-ligand Complexes using ab initio Calculations.
J. Chem. Inf. Model. 2019, 59, 10, 4195-4208. https://pubs.acs.org/doi/abs/10.1021/acs.
jcim.9b00373.
23. Grebner, Christoph; Malmerberg, Erik; Shewmaker, Andrew; Batista, Jose; Nicholls,
Anthony;and Sadowski, Jens. Virtual screening in the cloud: How big is big enough?
J. Chem. Inf. Model. 2020, 60, 9, 4274-4282. https://pubs.acs.org/doi/10.1021/acs.
jcim.9b00779.
Author Biography
Ashutosh Jogalekar is a computational chemist with
experience in preclinical drug discovery. Ashutosh has
worked for more than a decade in several startups where
he applied his expertise to identify and optimize small
molecule compounds for drug development. He also has worked in
product management, where he oversaw developing software solutions
for drug discovery cloud labs. Currently, Ashutosh serves as the Head of
Product at OpenEye, Cadence Molecular Sciences. In this role, he leads
the development of innovative software solutions at scale to help drug
discovery scientists accelerate their research. Ashutosh holds a PhD in
organic chemistry from Emory University.
APR Sept/Oct 2023
Table of Contents for the Digital Edition of APR Sept/Oct 2023
INSIDER INSIGHT - From Guidelines to Standards: Why Comprehensive AI Regulation is Essential to Spurring Innovation
BIOPHARMACEUTICAL - Aseptic Process Simulation: Cell and Gene Therapy Manufacture
FORMULATION & DEVELOPMENT - Challenges of Analytical Validation for ATMPs
QC Corner - The Intricacies of Testing for Mycoplasmas in Cell Culture Systems
MICROBIOLOGY - Standardized, Scalable And Efficient: Producing Recombinant Factor C to Quality Standards
FORMULATION AND DEVELOPMENT - R Code to Estimate Probability of Passing USP Dissolution Test
FORMULATION AND DEVELOPMENT - Cloud Computing for Drug Discovery: The Time is Now
CGT CIRCUIT - Navigating the Complex Testing Strategies for Viral Vector-based Gene Therapies
MANUFACTURING - Simplifying Finished Product Manufacturer Site Transfer Variations
FORMULATION AND DEVELOPMENT - Advancing Regulatory Compliance with Natural Language Processing
DRUG DELIVERY - Finding a Greater Vantage Point for Creating Green Therapies
WHITEPAPER - Microbial Testing for the Pharmaceutical Industry
Facility Tour - Eurofins BioPharma Product Testing
ROUNDTABLE - Drug Delivery
MANUFACTURING - Accelerating Biologics R&D with Unified Software and Data Flows
An Interview with Jason Downing, Senior Product Manager, TriLink BioTechnologies®
FORMULATION AND DEVELOPMENT - The Role of Data in the Pharmaceutical Lifecycle
BIOPHARMACEUTICAL - Uniting Quality Expectations on Reinvigorated Biopharma Campuses
WHITEPAPER - VITAMIN C – Tableting with LUBRITAB® RBW Lubricant
WHITEPAPER - Leveraging Analytical Technology Process for CMC
BIOPHARMACEUTICAL - Maximizing the Commercialization Potential of Cell and Gene Therapies
MICROBIOLOGY - Comments on Aseptic Process Simulation (APS) in the New EU GMP Annex 1
VENDOR VIEWPOINT - Continuous & Intervention-Free Microbial Monitoring
APR Sept/Oct 2023 - Cover1
APR Sept/Oct 2023 - Cover2
APR Sept/Oct 2023 - 1
APR Sept/Oct 2023 - 2
APR Sept/Oct 2023 - 3
APR Sept/Oct 2023 - 4
APR Sept/Oct 2023 - 5
APR Sept/Oct 2023 - 6
APR Sept/Oct 2023 - 7
APR Sept/Oct 2023 - 8
APR Sept/Oct 2023 - 9
APR Sept/Oct 2023 - 10
APR Sept/Oct 2023 - 11
APR Sept/Oct 2023 - 12
APR Sept/Oct 2023 - 13
APR Sept/Oct 2023 - 14
APR Sept/Oct 2023 - 15
APR Sept/Oct 2023 - 16
APR Sept/Oct 2023 - 17
APR Sept/Oct 2023 - 18
APR Sept/Oct 2023 - 19
APR Sept/Oct 2023 - 20
APR Sept/Oct 2023 - 21
APR Sept/Oct 2023 - 22
APR Sept/Oct 2023 - 23
APR Sept/Oct 2023 - 24
APR Sept/Oct 2023 - 25
APR Sept/Oct 2023 - 26
APR Sept/Oct 2023 - 27
APR Sept/Oct 2023 - 28
APR Sept/Oct 2023 - 29
APR Sept/Oct 2023 - 30
APR Sept/Oct 2023 - INSIDER INSIGHT - From Guidelines to Standards: Why Comprehensive AI Regulation is Essential to Spurring Innovation
APR Sept/Oct 2023 - 32
APR Sept/Oct 2023 - 33
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Aseptic Process Simulation: Cell and Gene Therapy Manufacture
APR Sept/Oct 2023 - 35
APR Sept/Oct 2023 - 36
APR Sept/Oct 2023 - 37
APR Sept/Oct 2023 - 38
APR Sept/Oct 2023 - 39
APR Sept/Oct 2023 - 40
APR Sept/Oct 2023 - 41
APR Sept/Oct 2023 - 42
APR Sept/Oct 2023 - 43
APR Sept/Oct 2023 - FORMULATION & DEVELOPMENT - Challenges of Analytical Validation for ATMPs
APR Sept/Oct 2023 - 45
APR Sept/Oct 2023 - 46
APR Sept/Oct 2023 - 47
APR Sept/Oct 2023 - 48
APR Sept/Oct 2023 - 49
APR Sept/Oct 2023 - QC Corner - The Intricacies of Testing for Mycoplasmas in Cell Culture Systems
APR Sept/Oct 2023 - 51
APR Sept/Oct 2023 - MICROBIOLOGY - Standardized, Scalable And Efficient: Producing Recombinant Factor C to Quality Standards
APR Sept/Oct 2023 - 53
APR Sept/Oct 2023 - 54
APR Sept/Oct 2023 - 55
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - R Code to Estimate Probability of Passing USP Dissolution Test
APR Sept/Oct 2023 - 57
APR Sept/Oct 2023 - 58
APR Sept/Oct 2023 - 59
APR Sept/Oct 2023 - 60
APR Sept/Oct 2023 - 61
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - Cloud Computing for Drug Discovery: The Time is Now
APR Sept/Oct 2023 - 63
APR Sept/Oct 2023 - 64
APR Sept/Oct 2023 - 65
APR Sept/Oct 2023 - 66
APR Sept/Oct 2023 - 67
APR Sept/Oct 2023 - CGT CIRCUIT - Navigating the Complex Testing Strategies for Viral Vector-based Gene Therapies
APR Sept/Oct 2023 - 69
APR Sept/Oct 2023 - MANUFACTURING - Simplifying Finished Product Manufacturer Site Transfer Variations
APR Sept/Oct 2023 - 71
APR Sept/Oct 2023 - 72
APR Sept/Oct 2023 - 73
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - Advancing Regulatory Compliance with Natural Language Processing
APR Sept/Oct 2023 - 75
APR Sept/Oct 2023 - 76
APR Sept/Oct 2023 - 77
APR Sept/Oct 2023 - DRUG DELIVERY - Finding a Greater Vantage Point for Creating Green Therapies
APR Sept/Oct 2023 - 79
APR Sept/Oct 2023 - 80
APR Sept/Oct 2023 - 81
APR Sept/Oct 2023 - WHITEPAPER - Microbial Testing for the Pharmaceutical Industry
APR Sept/Oct 2023 - 83
APR Sept/Oct 2023 - 84
APR Sept/Oct 2023 - 85
APR Sept/Oct 2023 - Facility Tour - Eurofins BioPharma Product Testing
APR Sept/Oct 2023 - 87
APR Sept/Oct 2023 - 88
APR Sept/Oct 2023 - ROUNDTABLE - Drug Delivery
APR Sept/Oct 2023 - 90
APR Sept/Oct 2023 - 91
APR Sept/Oct 2023 - MANUFACTURING - Accelerating Biologics R&D with Unified Software and Data Flows
APR Sept/Oct 2023 - 93
APR Sept/Oct 2023 - An Interview with Jason Downing, Senior Product Manager, TriLink BioTechnologies®
APR Sept/Oct 2023 - 95
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - The Role of Data in the Pharmaceutical Lifecycle
APR Sept/Oct 2023 - 97
APR Sept/Oct 2023 - 98
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Uniting Quality Expectations on Reinvigorated Biopharma Campuses
APR Sept/Oct 2023 - 100
APR Sept/Oct 2023 - 101
APR Sept/Oct 2023 - WHITEPAPER - VITAMIN C – Tableting with LUBRITAB® RBW Lubricant
APR Sept/Oct 2023 - 103
APR Sept/Oct 2023 - WHITEPAPER - Leveraging Analytical Technology Process for CMC
APR Sept/Oct 2023 - 105
APR Sept/Oct 2023 - 106
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Maximizing the Commercialization Potential of Cell and Gene Therapies
APR Sept/Oct 2023 - 108
APR Sept/Oct 2023 - 109
APR Sept/Oct 2023 - MICROBIOLOGY - Comments on Aseptic Process Simulation (APS) in the New EU GMP Annex 1
APR Sept/Oct 2023 - 111
APR Sept/Oct 2023 - 112
APR Sept/Oct 2023 - 113
APR Sept/Oct 2023 - VENDOR VIEWPOINT - Continuous & Intervention-Free Microbial Monitoring
APR Sept/Oct 2023 - 115
APR Sept/Oct 2023 - 116
APR Sept/Oct 2023 - 117
APR Sept/Oct 2023 - 118
APR Sept/Oct 2023 - 119
APR Sept/Oct 2023 - 120
APR Sept/Oct 2023 - Cover3
APR Sept/Oct 2023 - Cover4
https://www.nxtbookmedia.com